Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
INTSthis companyIntensity Therapeutics, Inc.	$2.93	-1.2×	1.17×	0×	-0.18×	143.3%	0.0%	0.0%	0.0%	-97.7%	-99.9%	-66.3%	0.01×	1.02×	0×	5.92×	0.0%	2	-10.06	3	B
ANTXAN2 Therapeutics, Inc.	$4.00	-0.98×	0.65×	0×	-0.41×	-86.4%	0.0%	0.0%	0.0%	-66.3%	-71.6%	-86.6%	0×	0.57×	0×	6.87×	0.0%	1	12.25	1	C-
BOLDBoundless Bio, Inc.	$2.41	-0.46×	0.27×	0×	-1.02×	-159.7%	0.0%	0.0%	0.0%	-59.0%	-43.0%	-175.9%	0.5×	-0.55×	0×	8.74×	0.0%	1	-3.14	2	C
IBIOiBio, Inc.	$0.78	-5.47×	2.12×	1,821.05×	-4×	-38.6%	100.0%	-35141.0%	-33044.0%	-38.6%	-40.0%	-13.1%	0.03×	1.7×	-663.04×	7.85×	0.0%	2	-3.05	2	C+
NXTCNextCure, Inc.	$5.68	-0.72×	1.15×	0×	-0.36×	17.9%	0.0%	0.0%	0.0%	-159.8%	-141.8%	-123.0%	0.15×	0.39×	0×	4.14×	0.0%	1	-32.41	2	B-
QTTBQ32 Bio Inc.	$9.47	1.37×	0.97×	0.76×	0.25×	5.9%	100.0%	31.5%	55.5%	71.0%	29.5%	-82.1%	0.37×	-1.05×	15.37×	4.85×	0.0%	5	15.46	5	A+
Peer median	—	-0.72×	0.97×	0×	-0.41×	-38.6%	0.0%	0.0%	0.0%	-59.0%	-43.0%	-86.6%	0.15×	0.39×	0×	6.87×	0.0%	1	-3.05	2	—